Besides the mutational state of KIT and PDGFRA, the secondary resistance of GIST to IM might be due to the activation of alternative signaling pathways ongoing after the inhibition of KIT/PDGFRA signaling. This evidence concerns the gene KIT and gastrointestinal stromal tumor.